Anaveon to Present New Data on ANV700 and ANV600 at SITC 2024 Annual Meeting

Anaveon, a clinical-stage immuno-oncology company based in Basel, Switzerland, has announced its participation in the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, which will be held from November 8 to November 10, 2024, in Houston, Texas. The company will be presenting posters on its innovative therapeutic candidates, ANV700 and ANV600.

ANV700 is a potent PD-1 targeted therapeutic designed to focus IL-21 signaling on T cells within the tumor microenvironment, aiming to reverse T cell exhaustion. Christoph Huber, Chief Scientific Officer of Anaveon, expressed confidence in ANV700's potential and stated that the company plans to advance the molecule into clinical studies to evaluate its therapeutic benefits for patients. The poster presentation for ANV700, numbered #960 and titled "ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells," will be available on Saturday, November 9, from 12:15 to 1:45 pm CST. The authors of this poster include A. Rau, N. Egli, P. Murer, L. Petersen, C. Stocker, K. Richter, and C. Huber.

Additionally, Anaveon will present new mechanistic data on ANV600, a therapeutic currently in clinical development. ANV600 acts as a cis-signaling αPD-1/IL-2Rβ/γ agonist, expanding both CD4+ and CD8+ tumor-specific T cells by targeting the tumor microenvironment and draining lymph nodes. The poster presentation for ANV600, numbered #954 and titled "ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes," will also be shared on Saturday, November 9, during the same time slot as ANV700. The authors for this poster are P. Murer, A. Zurbach, L. Petersen, N. Egli, A. Katopodis, and C. Huber.

Anaveon's research focuses on developing selective cytokine receptor agonists to enhance the immune system's response to tumors. One of its lead compounds, ANV419, is currently in Phase II studies for multiple cancer indications. ANV419 is engineered to preferentially signal through the IL-2 beta/gamma receptor, leading to significant proliferation of effector cells in patients. Another compound, ANV600, targets the selective IL-2 receptor moiety to intratumoral effector cells and shows promise for therapeutic benefits in less immunogenic tumors. These innovative therapeutics, if approved, could have broad applications in oncology, including potential use in combination with checkpoint inhibitors, cell therapies, vaccines, and radiotherapy.

Anaveon leverages its expertise in immunology and protein engineering to develop medicines that offer meaningful benefits to cancer patients. The company's lead compounds, ANV419 and ANV600, are in clinical trials for solid tumors, showcasing Anaveon's commitment to advancing cancer treatment through innovative approaches.